Jin RJ - Search Results

1

Suppression of clusterin expression enhanced cisplatin-induced cytotoxicity on renal cell carcinoma cells.

Lee CH, Jin RJ, Kwak C, Jeong H, Park MS, Lee NK, Lee SE. Lee CH, et al. Among authors: jin rj. Urology. 2002 Sep;60(3):516-20. doi: 10.1016/s0090-4295(02)01806-x. Urology. 2002. PMID: 12350509

2

Enhanced chemosensitivity of bladder cancer cells to cisplatin by suppression of clusterin in vitro.

Chung J, Kwak C, Jin RJ, Lee CH, Lee KH, Lee SE. Chung J, et al. Among authors: jin rj. Cancer Lett. 2004 Jan 20;203(2):155-61. doi: 10.1016/j.canlet.2003.07.008. Cancer Lett. 2004. PMID: 14732223

3

The application of an anti-angiogenic gene (thrombospondin-1) in the treatment of human prostate cancer xenografts.

Jin RJ, Kwak C, Lee SG, Lee CH, Soo CG, Park MS, Lee E, Lee SE. Jin RJ, et al. Cancer Gene Ther. 2000 Dec;7(12):1537-42. doi: 10.1038/sj.cgt.7700266. Cancer Gene Ther. 2000. PMID: 11228532

4

Thrombospondin-1, vascular endothelial growth factor expression and their relationship with p53 status in prostate cancer and benign prostatic hyperplasia.

Kwak C, Jin RJ, Lee C, Park MS, Lee SE. Kwak C, et al. Among authors: jin rj. BJU Int. 2002 Feb;89(3):303-9. doi: 10.1046/j.1464-4096.2001.01417.x. BJU Int. 2002. PMID: 11856116

5

Development of a new plasmid vector with PSA-promoter and enhancer expressing tissue-specificity in prostate carcinoma cell lines.

Lee SE, Jin RJ, Lee SG, Yoon SJ, Park MS, Heo DS, Choi H. Lee SE, et al. Among authors: jin rj. Anticancer Res. 2000 Jan-Feb;20(1A):417-22. Anticancer Res. 2000. PMID: 10769689

6

Foxa2 activates the transcription of androgen receptor target genes in castrate resistant prostatic tumors.

Connelly ZM, Yang S, Chen F, Yeh Y, Khater N, Jin R, Matusik R, Yu X. Connelly ZM, et al. Am J Clin Exp Urol. 2018 Oct 20;6(5):172-181. eCollection 2018. Am J Clin Exp Urol. 2018. PMID: 30510969 Free PMC article.

7

The nuclear factor-kappaB pathway controls the progression of prostate cancer to androgen-independent growth.

Jin RJ, Lho Y, Connelly L, Wang Y, Yu X, Saint Jean L, Case TC, Ellwood-Yen K, Sawyers CL, Bhowmick NA, Blackwell TS, Yull FE, Matusik RJ. Jin RJ, et al. Cancer Res. 2008 Aug 15;68(16):6762-9. doi: 10.1158/0008-5472.CAN-08-0107. Cancer Res. 2008. PMID: 18701501 Free PMC article.

8

SPARCL1 suppresses metastasis in prostate cancer.

Xiang Y, Qiu Q, Jiang M, Jin R, Lehmann BD, Strand DW, Jovanovic B, DeGraff DJ, Zheng Y, Yousif DA, Simmons CQ, Case TC, Yi J, Cates JM, Virostko J, He X, Jin X, Hayward SW, Matusik RJ, George AL Jr, Yi Y. Xiang Y, et al. Among authors: jin x, jin r. Mol Oncol. 2013 Dec;7(6):1019-30. doi: 10.1016/j.molonc.2013.07.008. Epub 2013 Jul 20. Mol Oncol. 2013. PMID: 23916135 Free PMC article.

9

Blocking GRP/GRP-R signaling decreases expression of androgen receptor splice variants and inhibits tumor growth in castration-resistant prostate cancer.

Case TC, Merkel A, Ramirez-Solano M, Liu Q, Sterling JA, Jin R. Case TC, et al. Transl Oncol. 2021 Nov;14(11):101213. doi: 10.1016/j.tranon.2021.101213. Epub 2021 Aug 27. Transl Oncol. 2021. PMID: 34461557 Free PMC article.

10

MicroRNA-21 deficiency suppresses prostate cancer progression through downregulation of the IRS1-SREBP-1 signaling pathway.

Kanagasabai T, Li G, Shen TH, Gladoun N, Castillo-Martin M, Celada SI, Xie Y, Brown LK, Mark ZA, Ochieng J, Ballard BR, Cordon-Cardo C, Adunyah SE, Jin R, Matusik RJ, Chen Z. Kanagasabai T, et al. Among authors: jin r. Cancer Lett. 2022 Jan 28;525:46-54. doi: 10.1016/j.canlet.2021.09.041. Epub 2021 Oct 2. Cancer Lett. 2022. PMID: 34610416

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

58 results

Search Page

Filters